ZIOPHARM Oncology, Inc. and Intrexon Corporation Announce Presentation of Data Highlighting Regulated Gene Expression System in Tumor-Homing Mesenchymal Stem Cells

Published: Oct 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON and GERMANTOWN, Md., Oct. 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of a preclinical study demonstrating the potential for using Intrexon's regulated gene expression system, the RheoSwitch Therapeutic System® (RTS®), in human mesenchymal stem cells (hMSCs). The study, "Regulated Immunomodulators Expression Using the RheoSwitch Therapeutic System® (RTS®) Platform in Human Mesenchymal Stem Cells," will be presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is taking place October 19-23, 2013 in Boston.

Help employers find you! Check out all the jobs and post your resume.

Back to news